Advertisement

Virtual reality: the promise and pitfalls of going virtual

  • Hal Broderson
Article
  • 133 Downloads

Because of their scale and cost advantages, virtual biotechs are attracting growing interest again. In theory, any element in the innovation chain of a biotech or medical device firm can be outsourced. In practice, the virtual model represents challenges to both investors and management.

References

  1. 1.
    Barthelemy, J. & Adsit, D. The Seven Deadly Sins of Outsourcing. Academy of Management Executives report, 17, 87–101 (2003).Google Scholar
  2. 2.
    Arbaugh, J.B. Outsourcing intensity, strategy, and growth in entrepreneurial firms. Journal of Enterprising Culture 11, 89–110 (2003).Google Scholar
  3. 3.
    Guithes-Amrhein, D. & Katz, J.A. Cash Flow as a Factor in the Mortality Risk of a Business. Proceedings of the 43rd ICSB World Conference “Entrepreneurship at the Threshold of the 21st Century,” June 9, 1998, Singapore Suntec Center (International Council of Small Business, Washington, DC 1998).Google Scholar
  4. 4.
    Hamilton, D. Biotech's dismal bottom line: more than $40 billion in losses. The Wall Street Journal May 20 (2004), p.1.Google Scholar
  5. 5.
    Bernstein, K. & Flores, D. Innovation and Economics. Biocentury, 13, A3 ( Sep 5, 2005).Google Scholar
  6. 6.
    Mack, G.S. Early-stage exits: Sometimes, less is more. Bioentrepreneur, 10.1038/bioent865 (June 2, 2005)Google Scholar

Copyright information

© Nature Publishing Group 2005

Authors and Affiliations

  • Hal Broderson
    • 1
  1. 1.Hal Broderson is at Rock Hill Ventures, 100 Front Street, Suite 1350, West Conshohocken, Pennsylvania 19428, USA. hal@rockhillventures.com

Personalised recommendations